Vancomycin taper and pulse regimen with careful follow-up for patients with recurrent clostridium dificile infection

Clinical Infectious Diseases

Volumn 65, Issue 8, 2017, Pages 1396-1399

  Sirbu, Benjamin D ^a,b   Soriano, Melinda M ^c   Manzo, Carl ^a,d   Lum, Jessica ^a,e   Gerding, Dale N ^a,b   Johnson, Stuart ^a,b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b HINES VA HOSPITAL   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

C. dificile; Pulse; Recurrence; Taper; Vancomycin

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FECES; FEMALE; FOLLOW UP; HOSPICE CARE; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RECURRENT INFECTION; RETREATMENT; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; CLOSTRIDIUM INFECTION; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 85032814382     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix529     Document Type: Article

References (12)

1. Cohen SH, Gerding DN, Johnson S, et al; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-55.
2. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985; 80:867-8.
3. McFarland LV, Elmer G W, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769-75.
4. Johnson S, Schriever C, Galang M, Kelly C P, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44:846-8.
5. Johnson S, Schriever C, Patel U, Patel T, Hecht D W, Gerding DN. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009; 15:290-1.
6. Soriano MM, Danziger LH, Gerding DN, Johnson S. Novel fidaxomicin treatment regimens for patients with multiple Clostridium difficile infection recurrences that are refractory to standard therapies. Open Forum Infect Dis 2014; 1:ofu069.
7. Louie TJ, Miller MA, Mullane KM, et al; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-31.
8. Wilcox MH, Gerding DN, Poxton IR, et al; MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 2017; 376:305-17.
9. Drekonja D, Reich J, Gezahegn S, et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann Intern Med 2015; 162:630-8.
10. Hota SS, Sales V, Tomlinson G, et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: an open-label, randomized controlled trial. Clin Infect Dis 2017; 64:265-71.
11. Majors D, Ellis P. Risk factors for recurrent Clostridium difficile infections and strategies to decrease readmissions in a community hospital. Hosp Pharm 2015; 50:1003-10.
12. Nair S, Yadav D, Corpuz M, Pitchumoni CS. Clostridium difficile colitis: factors influencing treatment failure and relapse - a prospective evaluation. Am J Gastroenterol 1998; 93:1873-6.